Deepali Suri, President of ICON Biotech, has been published in Pharmaceutical Executive. Her article draws on insights from 163 biotech leaders across North America, EMEA and APAC, supported by a supplementary survey o...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Evolution in the outsourcing of clinical research
Partnership is an increasingly important criterium for bio/pharmaceutical sponsors as they seek more bespoke solutions and the flexibility of tailored, blended outsourcing models.
DiPietro, M. Elaboration, Expansion, and Evolution in Outsourcing of Clinical Research. Pharmaceutical Technology 2023 47 (12) 31–33
-
Harmonising outsourcing to keep clinical trials on track
In this article in Applied Clinical Trials, Debbie Gilmore, Vice President, Strategic Alliance Management outlines how strategic partnerships and partnership-driven approaches to outsourcing can be used to navigate an increasingly complex clinical research landscape.
-
The Pharma Letter Podcast: CRO sector surges in bio revolution
This episode of The Pharma Letter Podcast features an interview with ICON’s Chief Commercial Officer, George McMillan, who outlines how ICON is growing in size to take advantage of increasing demand for its services.
-
Modern partnerships with CROs
In this article in Contract Pharma, ICON SMEs share insight on strategic and blended outsourcing models and trends in today’s market.
-
ICON partners with US Government for clinical trials of Covid-19 vaccines
The article on Clinical Trials Arena reports that ICON will conduct a phase 2b clinical trial for the US BARDA-selected Covid-19 vaccine candidate as part of Project NextGen.
-
BARDA, ICON partner to execute next-gen COVID vaccine trial
This news article from Contract Pharma reports that ICON will execute a Phase 2b clinical trial to assess the relative efficacy of a next generation COVID-19 vaccine.
-
ICON in pact with BARDA for next-gen COVID vaccine trial
The piece from Seeking Alpha highlights that the trial is designed to evaluate the vaccine candidate selected by BARDA, which functions as part of the Administration for Strategic Preparedness and Response under the U.S. Department of Health and Human Services.
-
ICON to partner with US government agency to test COVID vaccine candidates
This news article from Reuters outlines that, as part of the collaboration with Biomedical Advanced Research and Development Authority, ICON will conduct a mid-stage trial of 10,000 participants to assess the efficacy of a next generation COVID-19 vaccine relative to currently available shots.
-
ICON to conduct U.S. government trial of next-gen COVID-19 vaccines
This news article, published on FIERCE Biotech, highlights that ICON is partnering with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) to conduct a clinical trial to evaluate next-generation vaccines for COVID-19.
-
LEO Pharma enters clinical trial partnership with ICON
This news article, published on PM Live, highlights how the partnership will advance trial execution within medical dermatology.
